Michael Gelband’s Vor Biopharma VOR Stock Holding History

Michael Gelband’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-251	Closed	-$217K	–	2844
2021 Q1	$217K	Buy	+251	New	+$212K	﹤0.01%	1840

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Michael Gelband's VOR Position: Q2 2021 in Review

Michael Gelband sold out of Vor Biopharma (VOR) in Q2 2021, closing a stake of 251 shares — an estimated $217K sold.

Michael Gelband first reported a position in VOR in Q1 2021 and held it in 1 quarter. The position peaked at $217K in Q1 2021. 51 funds tracked by Wall St. Rank hold VOR as of Q2 2021.

Michael Gelband reported no remaining Vor Biopharma position as of Q2 2021 after selling out during the quarter.
Michael Gelband sold 251 Vor Biopharma shares in Q2 2021, an estimated $217K.
Michael Gelband first reported a position in Vor Biopharma in Q1 2021 and held it in 1 quarter.
Michael Gelband's Vor Biopharma position peaked at $217K in Q1 2021.
51 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2021.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.